SI-BONE, Inc. (NASDAQ:SIBN) Stake Raised by Sei Investments Co.

Sei Investments Co. raised its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 98.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,174 shares of the company’s stock after acquiring an additional 28,880 shares during the quarter. Sei Investments Co. owned approximately 0.14% of SI-BONE worth $752,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Champlain Investment Partners LLC raised its holdings in shares of SI-BONE by 104.8% during the first quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock worth $40,158,000 after acquiring an additional 1,255,610 shares in the last quarter. Bellevue Group AG raised its stake in shares of SI-BONE by 810.5% during the 1st quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock worth $18,661,000 after purchasing an additional 1,014,756 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of SI-BONE by 22.8% during the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock valued at $25,685,000 after buying an additional 368,637 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of SI-BONE by 34.9% in the 4th quarter. Wellington Management Group LLP now owns 817,048 shares of the company’s stock valued at $17,150,000 after buying an additional 211,209 shares in the last quarter. Finally, Pier Capital LLC increased its holdings in SI-BONE by 80.7% in the second quarter. Pier Capital LLC now owns 377,001 shares of the company’s stock worth $4,875,000 after buying an additional 168,417 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insider Buying and Selling at SI-BONE

In other news, insider Anthony J. Recupero sold 3,305 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total transaction of $44,881.90. Following the completion of the transaction, the insider now directly owns 233,412 shares in the company, valued at $3,169,734.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Anthony J. Recupero sold 2,087 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $14.17, for a total transaction of $29,572.79. Following the sale, the insider now directly owns 236,717 shares in the company, valued at approximately $3,354,279.89. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Anthony J. Recupero sold 3,305 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total value of $44,881.90. Following the completion of the transaction, the insider now owns 233,412 shares of the company’s stock, valued at $3,169,734.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,019 shares of company stock valued at $349,879 in the last 90 days. 5.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have issued reports on SIBN shares. Needham & Company LLC reduced their target price on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Truist Financial reduced their price objective on shares of SI-BONE from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, Morgan Stanley lowered their target price on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.

SI-BONE Price Performance

Shares of SI-BONE stock opened at $13.45 on Wednesday. The company has a current ratio of 9.17, a quick ratio of 8.12 and a debt-to-equity ratio of 0.22. The firm has a fifty day simple moving average of $14.88 and a 200-day simple moving average of $14.65. The stock has a market capitalization of $554.21 million, a price-to-earnings ratio of -12.34 and a beta of 1.22. SI-BONE, Inc. has a 1-year low of $11.76 and a 1-year high of $22.56.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. The company had revenue of $39.97 million during the quarter, compared to analysts’ expectations of $38.95 million. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.27%. During the same period in the prior year, the company earned ($0.30) earnings per share. On average, sell-side analysts expect that SI-BONE, Inc. will post -0.89 earnings per share for the current year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.